

CURRENT REPORT 42/2020

November 23, 2020

Appointment of the new Management Board Member of Ryvu Therapeutics S.A.

The Management Board of Ryvu Therapeutics S.A. with its registered office in Cracow ("Company") hereby announces the appointment of Kamil Sitarz, Ph.D., MBA, to the Management Board of the Company for the position of the Management Board Member, effective from 23 November 2020.

At the same time Dr Kamil Sitarz, was promoted to the Chief Operating Officer position. He will hold an executive responsibility for design, implementation, and co-ordination of day-to-day business operations, as well as financial and performance management at the Company. Moreover, he will be in charge of establishing and implementing corporate policies, procedures and processes, as well as management of administrative and operational functions at the Company.

Below, the Company presents the bio of Dr Kamil Sitarz.

Dr Kamil Sitarz holds an M.Sc. degree in Biophysics from Jagiellonian University in Cracow and a Ph.D. degree in Human/Medical Genetics from Newcastle University (Newcastle upon Tyne, UK). He has also graduated from the joint Executive MBA program at Cracow School of Business CUE, EM Normandie Business School and AESE Business School. He is the co-author of a dozen of scientific publications in peer-reviewed journals.

Dr Kamil Sitarz joined the Company in 2013 as a Senior Scientist and Biology Leader. Subsequently, he was promoted to the position of Principal Investigator/Project Manager, and later to Director of R&D Biology Department. After the corporate split of the Company in 2019, dr Kamil Sitarz became the Head of R&D Operations.

Dr Kamil Sitarz does not perform any activity competitive to the activity carried out by the Company, he is not a partner in a competitive civil partnership, he is not a member of any bodies of other companies that might be competitors to the Company, he does not participate in any other competitive legal person as a member of its governing body, and is not listed in the Register of Insolvent Debtors.

Legal basis: Article 56 Section 1 Item 2 of the Polish Act on offerings – current and periodical information

Representatives of the Company:

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka – Vice President of the Management Board